DCT

1:26-cv-00467

Veloxis Pharma Inc v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00467, D. Del., 04/23/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware based on Defendants' business activities, revenue derived from the district, and previous consents to personal jurisdiction in the Court in other patent litigation matters.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic extended-release tacrolimus tablets constitutes an act of infringement of ten U.S. patents covering Plaintiff's branded drug, ENVARSUS XR®.
  • Technical Context: The dispute centers on formulations of tacrolimus, a calcineurin-inhibitor immunosuppressant drug critical for preventing organ rejection in kidney transplant patients.
  • Key Procedural History: The action was triggered by a "Paragraph IV Certification" notice letter from Zydus, dated March 11, 2026, informing Veloxis of its ANDA filing. In the letter, Zydus asserts that the patents-in-suit are not infringed and/or are invalid.

Case Timeline

Date Event
2007-05-30 Earliest Priority Date for all Patents-in-Suit
2014-03-04 U.S. Patent No. 8,664,239 Issued
2014-04-01 U.S. Patent No. 8,685,998 Issued
2017-01-24 U.S. Patent No. 9,549,918 Issued
2019-01-01 U.S. Patent No. 10,166,190 Issued
2020-12-15 U.S. Patent No. 10,864,199 Issued
2021-09-07 U.S. Patent No. 11,110,081 Issued
2021-09-21 U.S. Patent No. 11,123,331 Issued
2022-08-23 U.S. Patent No. 11,419,823 Issued
2024-09-10 U.S. Patent No. 12,083,103 Issued
2025-09-02 U.S. Patent No. 12,403,095 Issued
2026-03-11 Zydus sends Paragraph IV Notice Letter
2026-03-12 Earliest date Veloxis received Notice Letter
2026-04-23 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,664,239 - Tacrolimus for Improved Treatment of Transplant Patients

  • Patent Identification: U.S. Patent No. 8,664,239, issued March 4, 2014. Compl. ¶29

The Invention Explained

  • Problem Addressed: The patent describes tacrolimus as an immunosuppressant drug that exhibits large inter- and intra-patient variability in absorption and metabolism, making standardized dosing difficult and necessitating frequent blood monitoring to avoid toxicity or rejection Compl. ¶2 '199 Patent, col. 1:51-57
  • The Patented Solution: The invention is a method of treatment using a once-daily, extended-release oral dosage form of tacrolimus. This formulation is designed to release the drug over a very extended period, which provides an improved pharmacokinetic profile characterized by a lower peak concentration (Cmax), a later time to peak concentration (Tmax), and a higher minimum concentration (Cmin), thereby enhancing safety and efficacy '199 Patent, abstract '199 Patent, col. 5:9-22
  • Technical Importance: By enabling a once-daily dosing regimen with a more predictable pharmacokinetic profile, the invention improves patient compliance and reduces the risk of side effects associated with high peak drug concentrations '199 Patent, col. 4:10-25

Key Claims at a Glance

  • The complaint asserts at least claim 1 of the '239 Patent Compl. ¶56
  • Independent claim 1 of the '239 Patent recites a method of suppressing kidney rejection in a kidney transplant patient, comprising the elements of:
    • Orally administering once daily in the evening to the kidney transplant patient an extended release pharmaceutical composition comprising tacrolimus.
    • Wherein the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the colon.
    • Wherein the pharmaceutical composition provides a substantially zero order release profile.
    • Wherein the composition exhibits a specific in vitro dissolution profile (at least 8% released at 4 hours, 40% released within 10-14 hours, and less than 62% released within 15 hours).
  • The complaint does not explicitly reserve the right to assert dependent claims but makes a general allegation of infringement of "one or more claims" Compl. ¶56

U.S. Patent No. 8,685,998 - Tacrolimus for Improved Treatment of Transplant Patients

  • Patent Identification: U.S. Patent No. 8,685,998, issued April 1, 2014. Compl. ¶30

The Invention Explained

  • Problem Addressed: The patent identifies the poor water solubility of tacrolimus as a key challenge, leading to incomplete and variable absorption from the gastrointestinal tract '998 Patent, col. 1:33-39
  • The Patented Solution: The invention claims a solid dispersion of tacrolimus within a hydrophilic or water-miscible vehicle. This formulation is designed to present the drug in a dissolved or finely dispersed state upon administration, enhancing its solubility and absorption '998 Patent, abstract '998 Patent, col. 2:46-55
  • Technical Importance: This solid dispersion technology provides a way to overcome the inherent low solubility of tacrolimus, which is a critical barrier to achieving reliable oral bioavailability for the drug '998 Patent, col. 2:50-55

Key Claims at a Glance

  • The complaint asserts at least claim 1 of the '998 Patent Compl. ¶67
  • Independent claim 1 of the '998 patent recites a pharmaceutical composition comprising the elements of:
    • A solid dispersion of tacrolimus in a hydrophilic or water-miscible vehicle.
    • Wherein the vehicle has a melting point of at least 20° C.
    • Wherein the concentration of tacrolimus is between 0.01% and 20% w/w.
  • The complaint does not explicitly reserve the right to assert dependent claims but makes a general allegation of infringement of "one or more claims" Compl. ¶67

U.S. Patent No. 9,549,918 - Stabilized Tacrolimus Composition

  • Patent Identification: U.S. Patent No. 9,549,918, issued January 24, 2017 Compl. ¶31
  • Technology Synopsis: This patent addresses the chemical degradation of tacrolimus in pharmaceutical formulations, particularly the formation of an isomer known as 8-epitacrolimus. The invention discloses using a stabilizing agent, such as an organic acid, to maintain an acidic pH environment within the composition, thereby reducing the rate of degradation upon storage '190 Patent, abstract '190 Patent, col. 3:9-24
  • Asserted Claims: At least claim 1 Compl. ¶78
  • Accused Features: The entirety of Defendants' ANDA Products Compl. ¶79

U.S. Patent No. 10,166,190 - Stabilized Tacrolimus Composition

  • Patent Identification: U.S. Patent No. 10,166,190, issued January 1, 2019 Compl. ¶32
  • Technology Synopsis: Similar to the '918 patent, this invention focuses on stabilizing tacrolimus compositions against degradation. It claims a pharmaceutical composition comprising a solid dispersion of tacrolimus and a stabilizing agent capable of providing a pH below 7, which prevents or reduces the formation of degradation products like 8-epitacrolimus '190 Patent, abstract
  • Asserted Claims: At least claim 1 Compl. ¶89
  • Accused Features: The entirety of Defendants' ANDA Products Compl. ¶90

U.S. Patent No. 10,864,199 - Tacrolimus for Improved Treatment of Transplant Patients

  • Patent Identification: U.S. Patent No. 10,864,199, issued December 15, 2020 Compl. ¶33
  • Technology Synopsis: This patent relates to methods of using an extended-release, once-daily oral dosage form of tacrolimus to achieve specific pharmacokinetic profiles. The invention aims to provide improved bioavailability and a more consistent, predictable release compared to conventional immediate-release formulations '199 Patent, abstract
  • Asserted Claims: At least claim 14 Compl. ¶100
  • Accused Features: The entirety of Defendants' ANDA Products Compl. ¶101

The complaint asserts five additional patents ('081, '331, '823, '103, and '095) that are part of the same families and cover similar subject matter related to extended-release and stabilized tacrolimus formulations and methods of use Compl. ¶¶34-38 The infringement allegations for these patents are substantively identical to those for the patents detailed above Compl. ¶¶109-160

III. The Accused Instrumentality

Product Identification

  • Defendants' Abbreviated New Drug Application (ANDA) No. 221214 Products, which are extended-release tablets of tacrolimus in 0.75 mg, 1 mg, and 4 mg strengths Compl. ¶1

Functionality and Market Context

  • The accused products are generic versions of Plaintiff's ENVARSUS XR® product Compl. ¶2
  • The complaint alleges that by filing the ANDA, Defendants have represented to the FDA that their products have the same active ingredient, dosage form, route of administration, and strengths as ENVARSUS XR® Compl. ¶44
  • Furthermore, the ANDA filing necessarily represents that the accused products are bioequivalent to ENVARSUS XR® and are seeking approval for the same medical indications, namely the prophylaxis of organ rejection in kidney transplant patients Compl. ¶44

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or a detailed, element-by-element infringement analysis. The infringement theory is based on the nature of the ANDA filing itself. The complaint alleges that because Defendants' ANDA Products are represented to the FDA as being bioequivalent to and having the same key characteristics (active ingredient, dosage form, etc.) as Plaintiff's ENVARSUS XR® product, they will necessarily meet the limitations of the asserted claims upon approval and commercialization (Compl. ¶¶57; 68; 79; 90; 101; 111; 121; 131; 142; 152). This approach leaves the specific mapping of product features to claim elements as a matter for discovery and expert testimony.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "substantially in the colon"

  • Context and Importance: This term appears in method claims, such as claim 1 of the '239 Patent, and is central to defining the extended-release profile. Practitioners may focus on this term because its construction will determine the geographic location of drug release required by the claim and whether the accused product's release profile, which is designed to be bioequivalent to the branded product, meets this spatial requirement. The dispute may center on what percentage of the drug must be released in the colon to be considered "substantial."

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification's general discussion of delivering drugs to the lower GI tract to take advantage of reduced enzymatic degradation could support a reading where "substantial" does not require a majority of the drug to be released in the colon, but simply an amount sufficient to achieve the desired pharmacokinetic effect '199 Patent, col. 4:51-64
    • Evidence for a Narrower Interpretation: The patent includes scintigraphic data (e.g.,'199 Patent, Fig. 2) showing the location of the formulation over time, which could be used to argue for a more specific, quantifiable meaning of "substantial" release based on the observed disintegration in the ascending, transverse, and descending colon '199 Patent, col. 5:35-42

  • The Term: "solid dispersion"

  • Context and Importance: This term is fundamental to the composition claims, such as claim 1 of the '998 Patent. The definition of "solid dispersion" will be critical for determining infringement, as it dictates the physical state of the tacrolimus within the vehicle. Practitioners may focus on whether this term requires the drug to be molecularly dissolved (a solid solution) or merely finely particulated within the carrier.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The '190 Patent defines "solid dispersion" as a "drug substance or an active ingredient dispersed or dissolved in an inert vehicle," where the drug may be in the form of "particles, often very fine particulate material, or of individual molecules" '190 Patent, col. 5:56-62 This language suggests the term covers both particulate dispersions and molecular solutions.
    • Evidence for a Narrower Interpretation: The specification emphasizes the benefits of having the drug in a dissolved state to overcome poor solubility '998 Patent, col. 2:50-55 An argument could be made that the object of the invention is best achieved by a solid solution, potentially narrowing the term's scope to exclude simple particulate mixtures.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for all ten patents. The inducement theory is based on the allegation that Defendants' product labeling will instruct physicians and patients to administer the generic product in a manner that directly infringes the asserted method claims (e.g., Compl. ¶60; Compl. ¶71). The contributory infringement theory is based on the allegation that Defendants know their products are especially adapted for an infringing use and have no substantial non-infringing use (e.g., Compl. ¶61; Compl. ¶72).
  • Willful Infringement: While the complaint does not explicitly use the word "willful," it repeatedly alleges that Defendants had knowledge of the patents-in-suit prior to filing their ANDA (e.g., Compl. ¶64; Compl. ¶75). This allegation of pre-suit knowledge provides a potential basis for a willfulness claim. The complaint also asserts that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 (e.g., Compl. ¶65; Compl. ¶76).

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of claim construction and scope: can the pharmacokinetic and release profile limitations recited in the method claims (e.g., "release ... substantially in the colon" in the '239 Patent) be read to cover a product that is deemed bioequivalent to ENVARSUS XR® under FDA standards? The case may explore whether FDA bioequivalence legally or factually necessitates a finding of infringement under the patent-specific definitions.
  • A second central question will be one of validity: will the asserted claims, which cover various aspects of extended-release and stabilized tacrolimus formulations, withstand Defendants' challenges of obviousness (§ 103) and/or indefiniteness/lack of enablement (§ 112)? The court's analysis will likely focus on whether the claimed inventions represented a non-obvious advance over prior art tacrolimus formulations known at the time of the invention.
  • A key evidentiary question will be one of technical equivalence: does the Defendants' formulation, particularly its excipients and manufacturing process, result in a "solid dispersion" and a "stabilized" composition as those terms are defined by the patents? This will involve detailed analysis of the competing products' chemical and physical structures, moving the dispute beyond high-level representations of bioequivalence to the specific science of the formulations.
Loading Complaint